Related Experiment Video
Updated: May 5, 2026

Author Spotlight: Developing Acetyl-Click Assay for HAT1 Inhibitor Screening
Published on: January 26, 2024
Mechanistic characterization of a 2-thioxanthine myeloperoxidase inhibitor and selectivity assessment utilizing click
Jessica Ward1, Samantha N Spath, Brandon Pabst
1Cardiovascular and Metabolic Diseases Research Unit and ‡Medicinal Chemistry, Pfizer Worldwide Research and Development , Cambridge, Massachusetts 02139, United States.
Abstract:
Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the production of hypochlorous acid. Despite a high level of interest in MPO as a therapeutic target, there have been limited reports about MPO inhibitors that are suitable for evaluating MPO in pharmacological studies. 2-Thioxanthine, 3-(2-ethoxypropyl)-2-thioxo-2,3-dihydro-1H-purin-6(9H)-one (A), has recently been reported to inhibit MPO by covalently modifying the heme prosthetic group. Here we report a detailed mechanistic characterization demonstrating that A possesses all the distinguishing features of a mechanism-based inactivator. A is a time-dependent MPO inhibitor and displays saturable inactivation kinetics consistent with a two-step mechanism of inactivation and a potency (k(inact)/K(I) ratio) of 8450 ± 780 M⁻¹ s⁻¹. MPO inactivation by A is dependent on MPO catalysis and is protected by substrate. A reduces MPO compound I to compound II with a second-order rate constant of (0.801 ± 0.056) × 10⁶ M⁻¹ s⁻¹, and its irreversible inactivation of MPO occurs prior to release of the activated inhibitory species. Despite its relatively high selectivity against a broad panel of more than 100 individual targets, including enzymes, receptors, transporters, and ion channels, we demonstrate that A labels multiple other protein targets in the presence of MPO. By synthesizing an alkyne analogue of A and utilizing click chemistry-activity-based protein profiling, we present that the MPO-activated inhibitory species can diffuse away to covalently modify other proteins, as reflected by the relatively high partition ratio of A, which we determined to be 15.6. This study highlights critical methods that can guide the discovery and development of next-generation MPO inhibitors.
Insights
A novel myeloperoxidase (MPO) inhibitor, compound A, acts as a mechanism-based inactivator. However, its activated form can modify other proteins, highlighting the need for next-generation MPO inhibitors.
Area of Science:
- Biochemistry
- Pharmacology
Background:
- Myeloperoxidase (MPO) is a key enzyme in inflammation, making it a therapeutic target.
- Developing effective MPO inhibitors for pharmacological studies remains challenging.
Purpose of the Study:
- To mechanistically characterize the MPO inhibitor 2-Thioxanthine, 3-(2-ethoxypropyl)-2-thioxo-2,3-dihydro-1H-purin-6(9H)-one (A).
- To assess the selectivity and potential off-target effects of compound A.
Main Methods:
- Kinetic analysis of MPO inactivation by compound A.
- Assessing MPO catalysis dependence and substrate protection.
- Utilizing click chemistry-activity-based protein profiling to identify labeled proteins.
Main Results:
- Compound A is a time-dependent, mechanism-based MPO inactivator with a potency (k(inact)/K(I)) of 8450 ± 780 M⁻¹ s⁻¹.
- The MPO-activated inhibitory species of A can diffuse and covalently modify other proteins, with a partition ratio of 15.6.
- Compound A exhibits high selectivity against over 100 other targets but labels multiple proteins in the presence of MPO.
Conclusions:
- Compound A's mechanism-based inactivation of MPO is confirmed.
- The potential for off-target protein modification by the activated inhibitor necessitates careful consideration in drug development.
- This study provides insights for designing improved MPO inhibitors with enhanced specificity.

